Pharma Integrates is a premier forum uniting senior leaders across pharma, life sciences, and healthcare to confront the challenges reshaping the industry — from commercial model transformation and supply chain resilience to data integration and patient experience. As the flagship event within the Life Science Integrates portfolio, Pharma Integrates has established itself as the essential gathering for executives driving the shift toward a more connected, outcomes-focused, and equitable healthcare ecosystem.
As patent cliffs loom and demand for outcomes-based evidence grows, the traditional develop-patent-sell model is under pressure. How are pharmaceutical companies redesigning their commercial and operating models to shift toward outcomes-based approaches — competing and growing amid fragmented markets, heightened scrutiny on value and a high degree of risk?
Patients today expect a seamless, connected healthcare experience yet fragmented systems and organisational boundaries built around institutions rather than individuals persist. This panel explores why patient experience remains one of healthcare’s hardest challenges, and what genuine integration of care, data, and trust would actually require.
From pandemic-era shortages to geopolitical disruption and the cold-chain demands of next-generation biologics, the vulnerabilities in global pharma supply chains have never been more exposed – and the degree of risk is especially high. How do manufacturers, CDMOs, logistics partners, and regulators forge the alliances needed to create truly resilient supply networks that hold under pressure and minimise risk?
Trial failure is expensive for everyone, especially as protocols grow more complex and timelines compress. This session explores how transactional CRO/CDMO relationships are giving way to more integrated and effective strategies, including aligned incentives, co-developed adaptive designs, and embedded digital capabilities.
Healthcare generates more data than almost any other industry, yet a large gap between collection and meaningful clinical insight remains. This panel examines the infrastructure, governance, and AI capabilities needed to translate patient data into personalised treatment pathways and close the divide between data ambition and real-world impact. What could breaking down data silos ultimately mean for the future of care?
London is a diverse, interconnected hub with millions living, working and travelling throughout the city on a daily basis. This includes many of our own clients and people, and the wider business community. As the city’s population grows, challenges including affordable housing, transport and infrastructure improvements and upskilling require increased attention. We see it as our priority to help find the right solutions for London.
After almost two years of refurbishment, in 2014 we fully reopened our Embankment Place office in London, achieving the highest ever score under BREEAM, the world’s foremost environmental assessment method and rating system for buildings.
Address: PricewaterhouseCoopers LLP, 1 Embankment Place, London, WC2N 6RH
Tel: +44 (0)20 7583 5000
